2B4FA61A-C1A7-49BD-9438-2865D386EAF2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.006570302233904
- age_years
- 30
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.728
- G2M_CHECKPOINT+0.693
- MYC_TARGETS_V2+0.630
- MYC_TARGETS_V1+0.586
- DNA_REPAIR+0.505
- MITOTIC_SPINDLE+0.478
- UNFOLDED_PROTEIN_RESPONSE+0.320
- WNT_BETA_CATENIN_SIGNALING+0.244
- MTORC1_SIGNALING+0.241
- OXIDATIVE_PHOSPHORYLATION+0.188
Top 10 suppressed
- MYOGENESIS-0.442
- INFLAMMATORY_RESPONSE-0.404
- KRAS_SIGNALING_DN-0.391
- TNFA_SIGNALING_VIA_NFKB-0.375
- INTERFERON_ALPHA_RESPONSE-0.346
- COAGULATION-0.339
- ESTROGEN_RESPONSE_EARLY-0.317
- ALLOGRAFT_REJECTION-0.309
- INTERFERON_GAMMA_RESPONSE-0.309
- HYPOXIA-0.298
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C6A16A8F-0AB7-42E9-A068-15EECF2912D3 | — | — | 0.952 |
| 2 | 4938761D-0762-4984-A399-BC036D6D2140 | — | — | 0.952 |
| 3 | SRR934937 | — | — | 0.930 |
| 4 | SRR934879 | — | — | 0.924 |
| 5 | ERR2598206 | fetal | fetal | 0.920 |
| 6 | CA366342-0949-4941-8AE6-984BAF032886 | — | — | 0.920 |
| 7 | SAMN03290940 | — | — | 0.919 |
| 8 | ERR2598226 | fetal | fetal | 0.918 |
| 9 | BS_A0DYVX9J | high-grade glioma | — | 0.914 |
| 10 | TCGA-O2-A52S-01A-11R-A262-07 | — | cohortSQ2 | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.728 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.693 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.630 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.586 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.505 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.478 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.244 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.241 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.188 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.138 | Remibrutinib | — uncovered |
| PEROXISOME | 0.084 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.048 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.043 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.037 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.032 | Inavolisib | — uncovered |